Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.31 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.31 |
| ▸ | CCL2 | P13500 | 1/20 | 0.31 |
| ▸ | CCL5 | P13501 | 1/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22160261 | 0.89 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL25299218 | 0.89 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL16329223 | 0.86 | LMNA (0.52) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL421993 | 0.86 | APP (0.50) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL8772862 | 0.84 | LMNA (0.55) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL20875302 | 0.84 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL4731267 | 0.84 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL19640302 | 0.84 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL2191721 | 0.84 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL27818117 | 0.82 | APP (0.54) | APPLMNASLC6A6CYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674103-B2 | Lyotropic liquid crystal systems based on aromatic tetracarboxylic bisbenzoimidazole derivatives and methods for making | NITTO DENKO CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20110317102-A1 | LYOTROPIC LIQUID CRYSTAL SYSTEMS BASED ON AROMATIC TETRACARBOXYLIC BISBENZOIMIDAZOLE DERIVATIVES AND METHODS FOR MAKING | NITTO DENKO CORPORATION (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110317102-A1 | LYOTROPIC LIQUID CRYSTAL SYSTEMS BASED ON AROMATIC TETRACARBOXYLIC BISBENZOIMIDAZOLE DERIVATIVES AND METHODS FOR MAKING | LSS, BLK, BMX | APP 4510/4885LMNA 297/4885SLC6A6 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.